Idasanutlin

Idasanutlin (RG7388, RO5503781) is a second-generation, orally administered small-molecule antagonist of the murine double minute 2 (MDM2) oncoprotein, developed at F. Hoffmann-La Roche to inhibit the p53-MDM2 protein-protein interaction with substantially improved potency, selectivity, and pharmacokinetic properties relative to the first-generation clinical MDM2 antagonist RG7112. Designed through structure-based optimization of a pyrrolidine-carboxamide scaffold, idasanutlin binds the p53 pocket of MDM2 with an inhibitory concentration (IC50) of 6 nanomolar in cell-free competitive binding assays and demonstrates greater than 100-fold selectivity for p53 wild-type cancer cell lines over p53-mutant lines in cellular proliferation assays [1, 2]. Mechanistically, the compound prevents MDM2-mediated ubiquitination and proteasomal degradation of p53, restoring the transcriptional activity of the tumor suppressor and inducing dose-dependent cell cycle arrest in the G1 phase and apoptosis through upregulation of p21, PUMA, NOXA, and other canonical p53 target genes.

The clinical development program for idasanutlin has encompassed multiple tumor types and combination strategies. In a Phase I dose-escalation study in 99 patients with advanced solid tumors, the maximum tolerated dose on the selected daily-times-five schedule was 500 mg in the published literature for five days of a 28-day cycle, with dose-limiting toxicities of thrombocytopenia and neutropenia reflecting on-target p53 activation in hematopoietic progenitor cells [3]. A Phase I/Ib study in relapsed or refractory acute myeloid leukemia (AML) established the recommended Phase II dose at 600 mg in the published literature for five days in combination with cytarabine, producing a composite complete remission rate of 29 percent with a median duration of response of 6.4 months [4]. The pivotal Phase III MIRROS trial (NCT02545283), enrolling 447 patients with relapsed or refractory AML, evaluated idasanutlin 300 mg in the published literature plus cytarabine versus placebo plus cytarabine; the primary endpoint of overall survival in the TP53 wild-type intention-to-treat population was not met (median 8.3 versus 9.1 months; hazard ratio 1.08), despite a significantly higher overall response rate in the idasanutlin arm (38.8 versus 22.0 percent) [5]. A Phase 1b study of the chemotherapy-free combination of idasanutlin with the BCL-2 inhibitor venetoclax in 56 patients with relapsed or refractory AML demonstrated a composite complete remission rate of 34.3 percent at the recommended Phase II doses, with particularly favorable responses in patients harboring IDH1/2 or RUNX1 mutations [6]. A Phase II study in 27 patients with hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera demonstrated 50 percent complete hematologic response and a median 76 percent reduction in JAK2 V617F variant allele frequency at 32 weeks, though gastrointestinal toxicity limited treatment duration [7].

Pharmacokinetics are characterized by oral absorption with peak plasma concentration at 6 to 8 hours, an elimination half-life of approximately 30 hours, absolute oral bioavailability of 40.1 percent, very high plasma protein binding (greater than 99.9 percent bound fraction), and predominantly hepatic metabolism through CYP3A4 (approximately 80 percent of oxidative metabolism) with additional contributions from CYP2C8, UGT1A3, and biliary excretion [3, 8]. Fecal excretion accounts for 91.5 percent of administered radioactivity; urinary excretion of parent compound is negligible [8]. The principal adverse events across all clinical studies are gastrointestinal (diarrhea, nausea, vomiting) and hematologic (thrombocytopenia, neutropenia, febrile neutropenia), representing on-target p53 activation in rapidly dividing mucosal and hematopoietic tissues. Acquired resistance to prolonged MDM2 inhibitor exposure occurs primarily through selection of pre-existing TP53-mutant subclones, a mechanism that has informed combination strategies aimed at circumventing single-agent resistance [9]. This monograph reviews the chemistry, discovery, mechanism, pharmacokinetics, preclinical pharmacology, clinical evidence base, sourcing, handling, combination interactions, adverse-event profile, and a structured comparative assessment of five MDM2 antagonists against idasanutlin on five competency standards.